OBJECTIVE: To explore the clinical efficacy of human hepatitis B immunoglobulin combined with tenofovir in the treatment of patients with pregnancy complicated with chronic hepatitis B. METHODS: Totally 90 patients with pregnancy complicated with chronic hepatitis B admitted into Shaanxi Provincial People’s Hospital from Apr. 2017 to Apr. 2020 were extracted to be divided into the tenofovir group and the combination group via the random number table

with 45 cases in each group. The tenofovir group was treated with tenofovir

while the combination group received human hepatitis B immunoglobulin combined with tenofovir. The levels of hepatitis B virus（ HBV） DNA and T lymphocyte subsets were detected in two groups. The levels of alanine aminotransferase（ ALT） and aspartate aminotransferase（ AST） were measured by enzyme-linked immunosorbent assay. The normalization rate of ALT

negative rate of HBV DNA

positive rate of hepatitis B surface antigen（ HBsAg）

positive rate of hepatitis B surface antibody（ HBsAb） and success rate of blockade of mother-to-child transmission were compared between two groups. The levels of immunoglobulin（ Ig） A

IgM and IgG in neonates were determined by immunoturbidimetric method.RESULTS: After treatment

compared with the tenofovir group

the levels of HBV DNA

ALT and AST in the combination group were significantly lower

and the differences were statistically significant（ P < 0. 05）. After treatment

compared with the tenofovir group

the levels of CD8+in the combination group were significantly lower

while the levels of CD4+and CD3+were significantly higher

with statistically significant difference（ P < 0. 05）.Compared with the tenofovir group

the normalization rate of ALT

negative rate of HBV DNA and success rate of blockade of mother-to-child transmission in the combination group were significantly higher

and the differences were statistically significant（ P < 0. 05）. Compared with the tenofovir group

the positive rate of HBsAg

positive rate of HBsAb of neonates in the combination group were significantly lower

and the levels of IgA

IgM and IgG were significantly lower

and the differences were statistically significant（ P < 0. 05）. CONCLUSIONS: Human hepatitis B immunoglobulin combined with tenofovir in the treatment of pregnant patients with chronic hepatitis B can regulate the level of HBV DNA

improve the liver function and immune function of patients

promote the normalization rate of ALT and negative rate of HBV DNA

decrease the positive rate of HBsAg and positive rate of HBsA

and improve the neonatal immune function

with significant effect of blockade of mother-to-child transmission.